诺和诺德裁员9000人，默沙东关闭伦敦研发业务，礼来中国架构调整

医药经济报09-11

1.诺和诺德全球裁员9000人9月10日，诺和诺德宣布进行全公司范围的转型，旨在精简组织架构，提高决策速度，并将资源重新配置，以促进公司在糖尿病和肥胖症领域的增长。作为转型的一部分，诺和诺德计划在全球裁员约9000人，公司现有78400个职位，其中丹麦预计将裁员约5000人。此次转型体现了诺和诺德致力于满足不断增长的全球需求，同时也致力于在更具活力、以消费者为导向的肥胖症市场中竞争，近期的增长放缓...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2566167992?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-11 19:50","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2566167992","market":"us","top_or_hot":-1,"title":"诺和诺德裁员9000人，默沙东关闭伦敦研发业务，礼来中国架构调整","media":"医药经济报","content":"<div>\n<p>1.诺和诺德全球裁员9000人9月10日，诺和诺德宣布进行全公司范围的转型，旨在精简组织架构，提高决策速度，并将资源重新配置，以促进公司在糖尿病和肥胖症领域的增长。作为转型的一部分，诺和诺德计划在全球裁员约9000人，公司现有78400个职位，其中丹麦预计将裁员约5000人。此次转型体现了诺和诺德致力于满足不断增长的全球需求，同时也致力于在更具活力、以消费者为导向的肥胖症市场中竞争，近期的增长放缓...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122460095261067&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德裁员9000人，默沙东关闭伦敦研发业务，礼来中国架构调整</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德裁员9000人，默沙东关闭伦敦研发业务，礼来中国架构调整\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-11 19:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122460095261067&s=b><strong>医药经济报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1.诺和诺德全球裁员9000人9月10日，诺和诺德宣布进行全公司范围的转型，旨在精简组织架构，提高决策速度，并将资源重新配置，以促进公司在糖尿病和肥胖症领域的增长。作为转型的一部分，诺和诺德计划在全球裁员约9000人，公司现有78400个职位，其中丹麦预计将裁员约5000人。此次转型体现了诺和诺德致力于满足不断增长的全球需求，同时也致力于在更具活力、以消费者为导向的肥胖症市场中竞争，近期的增长放缓...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122460095261067&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122460095261067&s=b","article_id":"2566167992","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091122460095261067&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2566167992","pubTimestamp":1757591455,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"作为转型的一部分，诺和诺德计划在全球裁员约9000人，公司现有78400个职位，其中丹麦预计将裁员约5000人。与此同时，礼来中国也迅速调整架构。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","MRK":"默沙东","LU0097036916.USD":"贝莱德美国增长A2 USD","SG9999015978.USD":"利安颠覆性创新基金A","LU0861579265.USD":"联博低波幅策略股票基金A","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2063271972.USD":"富兰克林创新领域基金","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4559":"巴菲特持仓","NVO":"诺和诺德","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","O":"Realty Income Corp","SG9999002232.USD":"Allianz Global High Payout USD","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A"},"translate_title":"Novo Nordisk cuts 9,000 jobs, Merck closes London R&D business, and Eli Lilly adjusts its structure in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"O":0.9,"NVO":1},"content_text":"1.诺和诺德全球裁员9000人9月10日，诺和诺德宣布进行全公司范围的转型，旨在精简组织架构，提高决策速度，并将资源重新配置，以促进公司在糖尿病和肥胖症领域的增长。作为转型的一部分，诺和诺德计划在全球裁员约9000人，公司现有78400个职位，其中丹麦预计将裁员约5000人。此次转型体现了诺和诺德致力于满足不断增长的全球需求，同时也致力于在更具活力、以消费者为导向的肥胖症市场中竞争，近期的增长放缓就证明了这一点。过去几年，诺和诺德的快速扩张增加了组织复杂性和成本。此次转型旨在解决这一复杂性，以便诺和诺德能够加大对科研、商业能力和产能提升的投入，从而惠及数百万仍未得到治疗的患者。诺和诺德明确这次全面裁员包括区域员工和总部职能部门，预计到2026年底，年度总节省额将达到约80亿丹麦克朗。节省下来的资金将用于糖尿病和肥胖症领域的增长机会，包括商业执行计划和研发项目。裁员将立即实施，诺和诺德预计将在未来几个月内与受影响的员工进行沟通，并根据当地劳动力市场的法律要求进行谈判。2.默沙东关闭伦敦研发业务9月10日，路透社报道，默沙东表示，由于英国的商业环境充满挑战，将取消其在伦敦的研究业务，并将研究活动迁至主要位于美国的现有地点。这家美国制药商不再计划入驻国王十字车站的贝尔格罗夫大厦（Belgrove House），该大楼原定于2027年开业，此举将影响约125名员工。默沙东表示，其决定反映了英国在解决生命科学行业投资不足以及对创新药物和疫苗整体低估的问题上未能取得有意义的进展。该公司还计划在2025年底前腾出位于伦敦生物科学创新中心和弗朗西斯克里克研究所的实验室。2020年8月，默沙东宣布斥资13.1亿美元（10亿英镑）在英国伦敦建立早期研究中心，这是美国本土以外的第一个早期研发中心。该中心将被简单地命名为“伦敦探索研究中心”（London Discovery Research Center），将聚集伦敦地区的所有员工，研发重点将放在衰老疾病上，主要集中在神经科学这一风险较高但主要需求未得到满足的领域。3.礼来中国迎重磅人事变动9月9日晚，礼来中国宣布管理层变动，礼来中国抗肿瘤事业部副总裁尹航决定离开礼来，寻求外部发展机会，最后工作日为9月30日。尹航于2001年毕业于中国人民大学国际企业管理专业，毕业后曾任职于诺和诺德。2019年4月，尹航加入礼来中国，就任抗肿瘤事业部市场总监，其后又被任命为爱优特北区销售总监。尹航于2019年4月加入礼来中国，初期担任抗肿瘤事业部市场总监，后逐步晋升为区域业务高级总监、乳腺肿瘤线负责人，并于2021年8月接替钱江出任抗肿瘤事业部副总裁，直接向礼来中国总裁汇报。在职期间，尹航深度参与礼来与信达生物、和黄医药的战略合作，推动PD-1抑制剂达伯舒（信迪利单抗）和抗血管生成药物爱优特（呋喹替尼）的市场落地，强化了礼来在消化道肿瘤、肺癌等领域的布局。与此同时，礼来中国也迅速调整架构。自10月1日起，礼来中国将免疫事业部与抗肿瘤事业部合并为免疫与肿瘤事业部，这一新部门将由礼来中国现任免疫事业部副总裁忻晨芸掌舵。编辑：李咏诗版式编辑：于成林审校：马飞、张松第11批国采规则六大调整！申报资质、锚点价、中选名额等有变14亿美元收购辉瑞“弃子”，诺华图什么？鼓励创新、培育国际竞争力，生物制品联采反内卷www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566167992","isCrawlerRequest":true}